Sugi Predict

Sugi Predict / Compounds / SCHEMBL205800

SCHEMBL205800

SCHEMBL205800

COc1ccc2cc(-c3ccc(Br)cc3)sc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 2/20 0.48
▸ TP53 P04637 2/20 0.48
▸ NFKB1 P19838 2/20 0.48
▸ NFKB2 Q00653 2/20 0.48
▸ RELA Q04206 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ CA2 P00918 1/20 0.47
▸ ESR1 P03372 3/20 0.46
▸ ESR2 Q92731 3/20 0.46
▸ APP P05067 4/20 0.44
▸ HSD17B1 P14061 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31310542 0.90 NPC1 (0.56) HDAC6TP53NFKB1NFKB2RELA
SCHEMBL1665299 0.90 NPC1 (0.56) HDAC6TP53NFKB1NFKB2RELA
SCHEMBL6171301 0.84 ESR2 (0.68) HDAC6TP53NFKB1NFKB2RELA
SCHEMBL26625361 0.84 NPC1 (0.48) HDAC6TP53NFKB1NFKB2RELA
SCHEMBL6838658 0.84 APP (0.57) HDAC6TP53NFKB1NFKB2RELA
SCHEMBL3053766 0.84 APP (0.58) HDAC6TP53NFKB1NFKB2RELA
SCHEMBL6832572 0.84 ESR1 (0.58) HDAC6TP53NFKB1NFKB2RELA
SCHEMBL7641283 0.83 NPC1 (0.47) HDAC6TP53NFKB1NFKB2RELA
SCHEMBL7107469 0.83 ESR1 (0.51) HDAC6TP53NFKB1NFKB2RELA
SCHEMBL21735627 0.82 NFKB1 (0.45) HDAC6TP53NFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109821558-B Synthesis method of drug azoxifene intermediate for treating breast cancer 马建 2020-04-10 — — CN claimed
US-12558428-B2 Heterobifunctional compounds and their use in treating disease HALDA THERAPEUTICS OPCO, INC. (US) 2026-02-24 — — US disclosed
US-20250281623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2025-09-11 — — US disclosed
US-12275716-B2 Modulators of estrogen receptor proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2025-04-15 — — US disclosed
CN-110300744-B Compounds for optically active devices 爱尔兰眼力健公司 2023-09-15 — — CN disclosed
US-11753387-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-09-12 — — US disclosed
US-11753387-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-09-12 — — US disclosed
US-11753387-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-09-12 — — US disclosed
EP-3889135-B1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2023-08-02 — — EP disclosed
EP-3889135-B1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2023-08-02 — — EP disclosed
US-8273341-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-09-25 — — US disclosed
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 — — US disclosed
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 — — US disclosed
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 — — US disclosed
EP-2430014-A1 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2012-03-21 — — EP disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 — — US disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 — — US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 — — US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 — — US disclosed
WO-2010132601-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558428-B2 Heterobifunctional compounds and their use in treating disease BRCA1, H1-0, FOXM1 HDAC6 368/4885TP53 176/4885NFKB1 1499/4885
US-20250281623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE VHL, HMBS, BRCA1 HDAC6 264/4885TP53 6/4885NFKB1 1336/4885
US-20120157404-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 HDAC6 517/4885TP53 700/4885NFKB1 860/4885
US-12275716-B2 Modulators of estrogen receptor proteolysis and associated methods of use ADRM1, MDM2, ESR2 HDAC6 3736/4885TP53 45/4885NFKB1 765/4885
US-11753387-B2 Compounds for optically active devices PDE6C, PDE6A, PDE6D HDAC6 2371/4885TP53 4678/4885NFKB1 3368/4885
US-20100310512-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 HDAC6 517/4885TP53 700/4885NFKB1 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.